Suggested Reading

Artoun S, Birdsell L, Sawyer MB, et al: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebo-controlled study. J Clin Oncol 28:1054–1060, 2010.

Baldwin C, Spiro A, Ahern R, Emery PW: Oral nutritional interventions in malnourished patients with cancer: A systematic review and meta-analysis. J Natl Cancer Inst 104:371–385, 2012.

Bozzetti F, Mariani L: Defining and classifying cancer cachexia: A proposal by the SCRINIO Working Group. JPEN J Parenter Enteral Nutr 33:361–367, 2009.

Dodson S, Dobs A, Hancock ML, et al: The impact of less than 8% weight loss on overall survival in subjects with non-small cell lung cancer (NSCLC) treated in a phase IIb trial of GTx-024. J Clin Oncol 29(suppl): abstract 9117, 2011.

Evans WJ, Morley JE, Argilés J, et al: Cachexia: A new definition. Clin Nutr 27:793–799, 2008.

Fearon K, Strasser F, Anker SD, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 12:489–495, 2011.

Garcia JM, Friend J, Allen S: Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: A multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 21:129–137, 2013.

Halfdanarson TR, Thordardottir E, West CP, et al: Does dietary counseling improve quality of life in cancer patients? A systematic review and meta-analysis. J Support Oncol 6:234–237, 2008.

Jatoi A, Dakhil SR, Nguyen PL, et al: A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: Results from N00C1 from the North Central Cancer Treatment Group. Cancer 110:1396–1403, 2007.

Jatoi A, Rowland K, Loprinzi CL, et al: An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 22:2469–2476, 2004.

Jatoi A, Windschitl HE, Loprinzi CL, et al: Dronabinol vs megestrol acetate vs both for cancer-associated anorexia: A North Central Cancer Treatment Group Study. J Clin Oncol 20:567–573, 2002.

Loprinzi CL, Kugler JW, Sloan JA, et al: Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 17:3299–3306, 1999.

Lundholm K, Körner U, Bunnebo L, et al: Insulin treatment in cancer cachexia: Effects on survival, metabolism, and physical functioning. Clin Cancer Res 13:2699–2706, 2007.

Mann M, Koller E, Murgo A, et al: Glucocorticoid-like activity of megestrol. Arch Intern Med 157:1651–1656, 1997.

Moertel CG, Schutt AJ, Reitemeier RJ, et al: Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33:1607–1609, 1974.

Ravasco P, Monteiro-Grillo I, Marques Vidal P, et al: Impact of nutrition on outcome: A prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27:659–668, 2005.

Ravasco P, Monteiro-Grillo I, Vidal PM, et al: Dietary counseling improves patient outcomes: A prospective, randomized controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 23:1431–1438, 2005.

Rock CL: Dietary counseling is beneficial for the patient with cancer. J Clin Oncol 23:1348–1349, 2005.

Strasser F, Lutz TA, Maeder MT, et al: Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: A randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 98:300–308, 2008.

Tansley S, Gunawardena H: The evolving spectrum of polymyositis and dermatomyositis-moving towards clinicoserological syndromes: A critical review. Clin Rev Allergy Immunol 47:264–273, 2014.

Temel J, Currow D, Fearon K, et al: 1483O_PR - Anamorelin for the treatment of cancer anorexia-cachexia in NSCLC: Results from the phase 3 studies ROMANA 1 and 2. Ann Oncol 25:1–41, 2014.

Wang J, Guo G, Chen G, et al: Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 169:838–847, 2013.

Zhou X, Wang JL, Song Y, et al: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism lead to prolonged survival. Cell 142:531–543, 2010.